Neuromuscular junction as Achilles' heel
Yet another autoantibody?
Every contraction of skeletal muscle entails the release of acetylcholine (ACh) from the motor nerve terminal, its passage across a submicroscopic space, and combination with the postsynaptic ACh receptors (AChRs), which in turn triggers the events of muscle contraction. This tiny movement of ACh across a 70-nM gap not only is highly complex but is vulnerable to a wide variety of attacks or errors that may cause weakness or paralysis. Some examples include bacteria (8 different botulinum toxins, tetanus toxin), plants (curare), snakes (cobratoxin, bungarotoxin), black widow spiders (latrotoxin), frogs (histrionicotoxin), and, of course, humans (anti-cholinesterase war gases sarin, tabun).
Myasthenia gravis (MG), the iconic autoimmune disorder of the neuromuscular junction (NMJ), is manifested by weakness and fatigue of skeletal muscles. MG results from a deficit of available AChRs at NMJs due to an antibody-mediated autoimmune attack. By far the most common antibodies in MG are those directed against AChRs, and they are detectable in approximately 85% of patients by a standard radioimmunoassay. These antibodies can deplete AChRs by one or more of 3 mechanisms 1 : (1) cross-linking AChRs, which induces accelerated uptake and degradation by muscle cells; (2) complement binding, which damages the AChRs and NMJs; and (3) blocking the actual ACh binding sites, thereby preventing transmission. The severity of MG depends on how efficiently a given patient's repertoire of AChR antibodies can reduce the available AChRs. 2 What of the 15% to 20% of patients with generalized MG who do not have AChR antibodies detectable by radioimmunoassay? Early studies showed that these patients do indeed have antibodies with suspicious properties suggesting that they might cause MG 3, 4 : in most cases, the antibodies bound to skeletal muscle fibers in vitro. On passive transfer to mice, they significantly 3 reduced the numbers of junctional AChRs and the amplitudes of miniature endplate potentials (p , 0.001). Unlike AChR antibodies, they did not cause either accelerated degradation or blockade of the AChRs. These findings suggested that the antibodies either (1) were directed against some component of the NMJ different from the AChR but closely associated with it, or (2) had low affinity binding (and therefore might not show up in a fluid-based antibody assay). 5 Both of these possibilities have now been confirmed. Antibodies against other components of the NMJ, i.e., MuSK (muscle-specific protein kinase) 6, 7 9 and are being tested for their myasthenogenic potential. The identification of new pathogenic antibodies not only is of biological interest but also influences the clinical phenotype of the MG and appears to affect the patient's responsiveness to therapeutic agents. In the article by Gasperi et al. 10 in this issue of Neurology ® , antibodies to another key component of the NMJ, agrin, have been found, raising the possibility that they too may have a role in the pathogenesis of MG in some patients.
Role of agrin. Proper function of the NMJ requires that the release of ACh by motor nerves occur precisely at the sites of AChRs (figure). It is the job of the motor nerve to induce and maintain clustering of AChRs in exact apposition to the nerve terminals. Motor nerves secrete a special form of agrin ("z1"), which binds to its receptor molecule, Lrp4, and together they activate MuSK. Activated MuSK serves a complex function that results in the clustering of AChRs and postsynaptic structures of the NMJ. Because of the role of agrin in this mechanism, it seemed reasonable that antibodies to agrin could produce a myasthenic syndrome.
How can the pathogenicity of such antibodies be evaluated? Criteria for defining a pathogenic role of autoantibodies include the following In the case of anti-agrin antibodies, criteria 1 and 2 have been satisfied thus far. Anti-agrin antibodies were present in approximately 10% of patients in this series and in 15% of patients with MG in a prior reported series of 161 patients. 12 All 5 anti-agrin patients in this series had antibodies to other NMJ components, but nearly half of those in the series by Cossins et al. 12 had only antibodies to agrin. The antibodies bound appropriately to agrin in an ELISA assay and to agrin expressed by cultured HEK293 cells. Now it will be important to determine whether anti-agrin antibodies can affect the Achilles' heel at the NMJ and cause yet another myasthenic syndrome.
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DISCLOSURE Figure Role of agrin
Agrin released from the nerve binds to LRP4, and through a complex with MuSK induces clustering of AChRs, which is further stabilized by rapsyn. Dok7 is required for proper activation of MuSK by nerve-derived agrin. See text re autoantibodies that have been demonstrated to produce myasthenia gravis and those that have yet to achieve requirements for confirmation as pathogenic antibodies. ACh 5 acetylcholine; AChR 5 acetylcholine receptor; Dok7 5 docking protein 7; LRP4 5 low-density lipoprotein-related receptor 4; MuSK 5 muscle-specific protein kinase.
